NextCure(NXTC) - 2025 Q1 - Quarterly Results

Exhibit 99.1 NextCure Provides Business Update and Reports First Quarter 2025 Financial Results BELTSVILLE, Md. – May 1, 2025 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported first quarter 2025 financial results. "With our LNCB74 antibody-drug conjugate ("ADC") program completing cohort 2 in April 2025, we are progressing as plan ...